Hsbc Holdings PLC Has $58.91 Million Stock Holdings in DexCom, Inc. $DXCM

Hsbc Holdings PLC decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 43.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 886,284 shares of the medical device company’s stock after selling 673,312 shares during the period. Hsbc Holdings PLC’s holdings in DexCom were worth $58,910,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rehmann Capital Advisory Group bought a new stake in DexCom during the 4th quarter worth about $245,000. Employees Provident Fund Board bought a new position in shares of DexCom in the 4th quarter valued at about $145,352,000. Tulsa Wealth Advisors INC bought a new position in shares of DexCom in the 4th quarter valued at about $430,000. Bank of Hawaii boosted its stake in shares of DexCom by 5.5% in the 4th quarter. Bank of Hawaii now owns 7,734 shares of the medical device company’s stock valued at $513,000 after purchasing an additional 400 shares during the last quarter. Finally, Reflection Asset Management acquired a new stake in shares of DexCom during the 4th quarter worth approximately $25,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 46,694 shares of company stock valued at $3,343,977. Corporate insiders own 0.28% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $69.07 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $26.65 billion, a P/E ratio of 29.52, a PEG ratio of 1.13 and a beta of 1.45. The business has a 50-day moving average of $67.13 and a 200-day moving average of $67.98. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the company posted $0.32 EPS. DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, equities analysts anticipate that DexCom, Inc. will post 2.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DXCM. William Blair raised shares of DexCom to a “strong-buy” rating in a research note on Friday, May 15th. TD Cowen reaffirmed a “buy” rating and issued a $95.00 price objective (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. BTIG Research reaffirmed a “buy” rating and set a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Finally, Piper Sandler reissued an “overweight” rating and issued a $88.00 price target (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $84.83.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.